CymaBay Therapeutics Inc.

3.47+0.0300+0.87%Vol 666.05K1Y Perf -47.39%
Jul 8th, 2020 16:00 DELAYED
BID3.36 ASK3.48
Open3.48 Previous Close3.44
Pre-Market- After-Market3.47
 - -%  - -%
Target Price
8.18 
Analyst Rating
Strong Buy 1.10
Potential %
135.74 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★ —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap239.02M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
39.24 
Earnings Date
5th Aug 2020

Today's Price Range

3.363.52

52W Range

1.216.97

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
-0.86%
1 Month
-10.57%
3 Months
105.33%
6 Months
84.57%
1 Year
-47.39%
3 Years
-38.58%
5 Years
29.00%
10 Years
-

TickerPriceChg.Chg.%
CBAY3.470.03000.87
AAPL381.378.68002.33
GOOG1 496.0010.82000.73
MSFT212.834.58002.20
XOM43.14-0.1000-0.23
WFC24.550.09000.37
JNJ143.270.42000.29
FB243.582.72001.13
GE6.860.10001.48
JPM93.300.98001.06
Earnings HistoryEstimateReportedSurprise %
Q01 2020-0.31-0.1938.71
Q04 2019-0.39-0.3510.26
Q03 2019-0.37-0.38-2.70
Q02 2019-0.37-0.355.41
Q01 2019-0.34-0.37-8.82
Q04 2018-0.36-0.3211.11
Q03 2018-0.30-0.34-13.33
Q02 2018-0.25-0.30-20.00
Earnings Per EndEstimateRevision %Trend
6/2020 QR-0.2320.69Positive
9/2020 QR-0.2212.00Positive
12/2020 FY-0.9317.70Positive
12/2021 FY-1.05-14.13Negative
Next Report Date5th Aug 2020
Estimated EPS Next Report-0.23
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume666.05K
Shares Outstanding68.88M
Trades Count4.22K
Dollar Volume2.41M
Avg. Volume2.40M
Avg. Weekly Volume1.04M
Avg. Monthly Volume1.69M
Avg. Quarterly Volume3.38M

CymaBay Therapeutics Inc. (NASDAQ: CBAY) stock closed at 3.47 per share at the end of the most recent trading day (a 0.87% change compared to the prior day closing price) with a volume of 666.61K shares and market capitalization of 239.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. CymaBay Therapeutics Inc. CEO is Sujal Shah.

The one-year performance of CymaBay Therapeutics Inc. stock is -47.39%, while year-to-date (YTD) performance is 77.04%. CBAY stock has a five-year performance of 29%. Its 52-week range is between 1.21 and 6.97, which gives CBAY stock a 52-week price range ratio of 39.24%

CymaBay Therapeutics Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 1.33, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.56%, a ROC of -44.76% and a ROE of -43.38%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from CymaBay Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.23 for the next earnings report. CymaBay Therapeutics Inc.’s next earnings report date is 05th Aug 2020.

The consensus rating of Wall Street analysts for CymaBay Therapeutics Inc. is Strong Buy (1.1), with a target price of $8.18, which is +135.74% compared to the current price. The earnings rating for CymaBay Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CymaBay Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CymaBay Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.31, ATR14 : 0.27, CCI20 : -94.21, Chaikin Money Flow : -0.04, MACD : -0.01, Money Flow Index : 45.72, ROC : -15.98, RSI : 46.71, STOCH (14,3) : 19.79, STOCH RSI : 0.59, UO : 42.50, Williams %R : -80.21), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CymaBay Therapeutics Inc. in the last 12-months were: Sujal Shah (Buy at a value of $49 155)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (90.00 %)
8 (80.00 %)
3 (33.33 %)
Moderate Buy
1 (10.00 %)
1 (10.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (10.00 %)
6 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.10
Strong Buy
1.30
Moderate Buy
2.33

CymaBay Therapeutics Inc.

CymaBay Therapeutics Inc is a part of the healthcare sector based in the United States. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.

CEO: Sujal Shah

Teplephone: +1 510 293-8800

Address: 7575 Gateway Boulevard, Newark 94560, CA, USA

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

45%55%

Bearish Bullish

66%34%

News

Stocktwits